Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q2 2026
Maravai Lifesciences Holdings (MRVI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Maravai Lifesciences Holdings (MRVI) reported revenue of $51.4M for the second quarter 2026 (Q2 2026), +9% from a year earlier and -22% from the quarter before. Operating margin was -29.3%, net loss $21.6M (42.0% of revenue).
Maravai Lifesciences Holdings, Q2 2026: revenue $51.4M (+8% year over year), operating margin -29.3%, net loss $21.6M, operating cash flow $4.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $51.4M | -22% | +9% |
| Operating profit | −$15.1M | — | — |
| Net earnings | −$21.6M | — | — |
| Operating cash flow | $4.0M | -54% | — |
| Free cash flow | $3.6M | -14% | — |
What changed
Revenue was $51.4M in Q2 2026, up 9% year over year and down 22% from the previous quarter. TriLink was the largest line at 67% of revenue. TriLink added $3.6M year over year (up 12%), 89% of the total change.
Gross margin was 40.1%, up 23.8 points from Q2 2025. Operating costs exceeded revenue by $15.1M, an operating margin of -29.3%. Operating expenses fell 52% while revenue rose 9%. The quarter ended with a net loss of $21.6M, wider than the previous quarter's $6.4M loss. Minority interests bore $9.2M of it: to shareholders the quarter was a loss of $12.4M.
Operating cash flow was $4.0M. Non-cash charges added back $11.8M of depreciation and amortization and $10.2M of share-based compensation. Working capital and other items added $3.6M. Capital expenditures of $370K left free cash flow of $3.6M.
Questions
What was Maravai Lifesciences Holdings' revenue in the second quarter 2026?
Maravai Lifesciences Holdings (MRVI) reported revenue of $51.4M for the second quarter 2026 (Q2 2026), +9% from a year earlier and -22% from the quarter before.
Was Maravai Lifesciences Holdings profitable in the second quarter 2026?
Operating loss was $15.1M (-29.3% of revenue) and net loss $21.6M.